Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia

Leukemia

Volumn 26, Issue 6, 2012, Pages 1255-1265

  Spijkers Hagelstein, J A P ^a   Schneider, P ^a   Hulleman, E ^a   De Boer, J ^b   Williams, O ^b   Pieters, R ^a   Stam, R W ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

calcium signaling; MLL rearranged infant leukemia; prednisolone resistance; S100A8 and S100A9

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CALCIUM ION; CALGRANULIN A; CALGRANULIN B; DEXAMETHASONE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISOLONE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER PROGNOSIS; CANCER RESISTANCE; DOWN REGULATION; DRUG SENSITIVITY; HUMAN; INFANT; LEUKEMIA CELL; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

APOPTOSIS; BLOTTING, WESTERN; CALGRANULIN A; CALGRANULIN B; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE REARRANGEMENT; GLUCOCORTICOIDS; HUMANS; INFANT; INFANT, NEWBORN; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; PREDNISONE; PROGNOSIS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SRC-FAMILY KINASES; SURVIVAL RATE;

EID: 84862009683     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.388     Document Type: Article

References (45)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia 1996; 10: 372-377. (Pubitemid 26102900)
3. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240-250. (Pubitemid 47082422)
4. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia 1998; 12: 1344-1348. (Pubitemid 28442379)
5. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V et al. Corticosteroiddependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 1987; 199: 151-160. (Pubitemid 17079852)
6. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217. (Pubitemid 29380401)
7. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268. (Pubitemid 46606259)
8. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998; 92: 259-266. (Pubitemid 28303201)
9. Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG et al. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2010; 115: 1018-1025.
10. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW et al. Gene expressionbased chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-342. (Pubitemid 44512194)
11. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood 2010; 115: 2835-2844.
12. Qazi S, Uckun FM. Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets. Br J Haematol 2010; 149: 865-873.
13. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 1991; 266: 7706-7713. (Pubitemid 21906422)
14. Strupat K, Rogniaux H, Van Dorsselaer A, Roth J, Vogl T. Calcium-induced noncovalently linked tetramers of MRP8 and MRP14 are confirmed by electrospray ionization-mass analysis. J Am Soc Mass Spectrom 2000; 11: 780-788. (Pubitemid 34532588)
15. Teigelkamp S, Bhardwaj RS, Roth J, Meinardus-Hager G, Karas M, Sorg C. Calciumdependent complex assembly of the myeloic differentiation proteins MRP-8 and MRP-14. J Biol Chem 1991; 266: 13462-13467. (Pubitemid 21907367)
16. Kawasaki H, Nakayama S, Kretsinger RH. Classification and evolution of EF-hand proteins. Biometals 1998; 11: 277-295. (Pubitemid 29121537)
17. Carafoli E. Calcium signaling: a tale for all seasons. Proc Natl Acad Sci USA 2002; 99: 1115-1122. (Pubitemid 34139793)
18. Kaiser N, Edelman IS. Calcium dependence of glucocorticoid-induced lymphocytolysis. Proc Natl Acad Sci USA 1977; 74: 638-642.
19. Kaspers GJ, Veerman AJ, Pieters R, Broekema GJ, Huismans DR, Kazemier KM et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 1994; 70: 1047-1052. (Pubitemid 24358937)
20. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-2336.
21. Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2007; 110: 2774-2775. (Pubitemid 47523212)
22. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18 (Suppl 1): S96-104. (Pubitemid 41185642)
23. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds). Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer: New York, 2005, pp397-420.
24. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004; 20: 3705-3706. (Pubitemid 40136823)
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
26. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101: 1270-1276. (Pubitemid 36182495)
27. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008; 14: 355-368.
28. Stam RW, den Boer ML, Passier MM, Janka-Schaub GE, Sallan SE, Armstrong SA et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia 2006; 20: 264-271. (Pubitemid 43148664)
29. Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 2008; 8: 243-252. (Pubitemid 351881350)
30. Nicolas E, Ramus C, Berthier S, Arlotto M, Bouamrani A, Lefebvre C et al. Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients. Leukemia 2011; 25: 57-65.
31. Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel-Eibrink MM et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia 2011; 25: 1704-1710.
32. Bootman MD, Collins TJ, Peppiatt CM, Prothero LS, MacKenzie L, De Smet P et al. Calcium signalling-an overview. Semin Cell Dev Biol 2001; 12: 3-10.
33. Distelhorst CW, Dubyak G. Role of calcium in glucocorticosteroid-induced apoptosis of thymocytes and lymphoma cells: resurrection of old theories by new findings. Blood 1998; 91: 731-734. (Pubitemid 28078272)
34. Rizzuto R, Pinton P, Ferrari D, Chami M, Szabadkai G, Magalhaes PJ et al. Calcium and apoptosis: facts and hypotheses. Oncogene 2003; 22: 8619-8627. (Pubitemid 38019197)
35. Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996; 184: 1331-1341. (Pubitemid 26354689)
36. Duchen MR. Mitochondria and calcium: from cell signalling to cell death. J Physiol 2000; 529 (Pt 1): 57-68.
37. Smaili SS, Hsu YT, Youle RJ, Russell JT. Mitochondria in Ca2+ signaling and apoptosis. J Bioenerg Biomembr 2000; 32: 35-46.
38. Holleman A, den Boer ML, Kazemier KM, Janka-Schaub GE, Pieters R. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood 2003; 102: 4541-4546. (Pubitemid 37494122)
39. Ryckman C, Gilbert C, de Medicis R, Lussier A, Vandal K, Tessier PA. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J Leukoc Biol 2004; 76: 433-440. (Pubitemid 39006958)
40. McConkey DJ, Nicotera P, Hartzell P, Bellomo G, Wyllie AH, Orrenius S. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Arch Biochem Biophys 1989; 269: 365-370. (Pubitemid 19052317)
41. Minagawa N, Kruglov EA, Dranoff JA, Robert ME, Gores GJ, Nathanson MH. The anti-apoptotic protein Mcl-1 inhibits mitochondrial Ca2+ signals. J Biol Chem 2005; 280: 33637-33644. (Pubitemid 41397165)
42. Vrana JA, Bieszczad CK, Cleaveland ES, Ma Y, Park JP, Mohandas TK et al. An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine. Cancer Res 2002; 62: 892-900. (Pubitemid 34126970)
43. Srikrishna G. S100A8 and S100A9: New Insights into Their Roles in Malignancy. J Innate Immun 2011; 4: 31-40.
44. Kim LC, Song, L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6: 587-595.
45. Chen M, Sastry SK, O'Connor KL. Src kinase pathway is involved in NFAT5-mediated S100A4 induction by hyperosmotic stress in colon cancer cells. Am J Physiol Cell Physiol 2011; 300: C1155-C1163.